Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents ...
A vaccine created by University of Georgia researchers to battle multiple life-threatening fungal infections is also ...
In a recent Science Advances study, scientists have developed a novel nanozyme-probiotic combination therapy for Candida vaginitis, which shows potency in killing the causative pathogen, restoring ...
A recent study published in the journal Biomedicines aimed to determine the antifungal tolerance of Candida auris (C. auris) to all three classes of antifungal drugs commonly used to treat invasive ...
Candida auris, a multi-drug resistant yeast-like fungus, is emerging across the state, posing significant health challenges, ...
Experts are warning about a multi-drug resistant fungus known as a “superbug,” which has been detected in Connecticut.
The FDA’s advisory committee on antimicrobial drugs on Jan. 25 recommended rezafungin be approved to treat candidemia and invasive candidiasis in adults with limited or no alternative treatment option ...
Candida auris is a fast-spreading, drug-resistant fungus threatening hospitals worldwide, with limited treatments and urgent need for better diagnostics.
Credit: Melinta Therapeutics. Rezzayo is supplied as a solid (cake or powder) in a single-dose vial containing 200mg of rezafungin. Rezzayo ™ (rezafungin for injection) is now available for the ...
A dangerous fungus is spreading across hospitals and nursing homes nationwide, including in New York and New Jersey. Candida ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results